
Serotonin syndrome presenting as posterior reversible encephalopathy syndrome in the setting of combined selective serotonin reuptake inhibitors and attention-deficit/hyperactivity disorder therapy
Clinicians managing patients with attention-deficit/hyperactivity disorder should be vigilant about the underrecognized risk factor of polypharmacy in the development of serotonin syndrome. Read More









